CliffBio
biologic

Myalept

metreleptin

Loss of exclusivityFebruary 2026projected — 12-year biologic exclusivity estimate
CompanyChiesi Farmaceutici S.p.A. →See this company's full patent-cliff portfolio

Drug detail

Brand nameMyalept
Active ingredientmetreleptin
Strength11.3MG
Dosage formFor Injection
RouteSubcutaneous
ModalityBiologic
FDA approvalFebruary 2014
Marketing statusRx

More from Chiesi Farmaceutici S.p.A.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Myalept patent cliff — loss of exclusivity February 2026 | CliffBio